#1 Clinical Trials Search in Europe

Human Igg1 Lambda Monoclonal Antibody Against Alfa-Synuclein

This article discusses the ongoing clinical trials investigating the use of Human IgG1 Lambda Monoclonal Antibody Against Alfa-Synuclein, also known as TAK-341, for the treatment of Multiple System Atrophy (MSA). The trials aim to evaluate the drug’s efficacy, safety, tolerability, and effects on the human body in patients with MSA. The study is designed as a randomized, double-blind, placebo-controlled Phase 2 trial, focusing on various aspects of the disease progression and patient outcomes.

Table of Contents

What is TAK-341?

TAK-341 is a new medication being studied for the treatment of Multiple System Atrophy (MSA). It is classified as a human IgG1 lambda monoclonal antibody that targets a protein called alpha-synuclein[1]. In simpler terms, TAK-341 is a specially designed antibody (a type of protein used by the immune system) that can recognize and potentially neutralize a specific protein involved in MSA.

Target Condition: Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare, progressive neurological disorder that affects multiple parts of the body. It causes problems with movement, balance, and automatic body functions like blood pressure regulation and bladder control[1]. MSA is a serious condition that currently has no cure, which is why research into new treatments like TAK-341 is so important.

How TAK-341 Works

TAK-341 is designed to target alpha-synuclein, a protein that is believed to play a key role in the development of MSA. By binding to this protein, TAK-341 may help to slow down or stop the progression of the disease[1]. The medication is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein.

Clinical Trial Details

TAK-341 is currently being studied in a Phase 2 clinical trial. This trial is:

  • Randomized: Participants are randomly assigned to receive either TAK-341 or a placebo (a substance with no active medication).
  • Double-blind: Neither the participants nor the researchers know who is receiving TAK-341 or the placebo.
  • Placebo-controlled: The effects of TAK-341 are compared to those of a placebo.
The trial will last for 52 weeks (about one year) and will evaluate how well TAK-341 works and how safe it is for patients with MSA[1].

Potential Benefits

The main goal of the TAK-341 trial is to see if it can slow down the progression of MSA. Researchers will measure this using various scales that assess MSA symptoms, including:

  • The Unified Multiple System Atrophy Rating Scale (UMSARS), which measures the severity of MSA symptoms[1].
  • The Clinical Global Impression of Severity (CGI-S) scale, which gives an overall picture of how severe the condition is[1].
  • The Scales for Outcomes in Parkinson’s Disease – Autonomic Dysfunction (SCOPA-AUT), which assesses problems with automatic body functions[1].
If successful, TAK-341 could potentially improve the quality of life for people living with MSA.

Safety and Side Effects

As with any new medication, safety is a top priority in the TAK-341 trial. The researchers will carefully monitor participants for any side effects or adverse reactions. They will look at:

  • Treatment-emergent adverse events (TEAEs), which are any new medical problems that occur during the trial[1].
  • Changes in laboratory tests, vital signs, and heart activity (ECG)[1].
  • Any signs of suicidal thoughts or behaviors, using a tool called the Columbia-Suicide Severity Rating Scale (C-SSRS)[1].
It’s important to note that potential side effects are not yet fully known, as this is an early-stage trial.

Eligibility Criteria

Not everyone with MSA will be eligible to participate in this trial. Some key eligibility criteria include:

  • Age: Participants must be at least 40 years old[1].
  • MSA Diagnosis: Participants must have a diagnosis of possible or probable MSA[1].
  • Disease Duration: The onset of MSA symptoms must have occurred within 4 years before screening[1].
  • Symptom Severity: Participants must have a certain level of symptom severity, as measured by the UMSARS scale[1].
There are also several exclusion criteria, such as certain medical conditions or medications that would make it unsafe for a person to participate in the trial.

Conclusion

TAK-341 represents a promising new approach to treating Multiple System Atrophy, a condition for which there is currently no cure. While the results of this clinical trial are not yet known, the research offers hope for people living with MSA. As with any experimental treatment, it’s important to remember that more research is needed to fully understand the effectiveness and safety of TAK-341. Patients interested in this or other clinical trials should discuss their options with their healthcare provider.

Aspect Details
Study Type Randomized, Double-blind, Placebo-Controlled, Phase 2
Drug Name TAK-341 (Human IgG1 Lambda Monoclonal Antibody Against Alfa-Synuclein)
Condition Multiple System Atrophy (MSA)
Primary Objective Evaluate efficacy of TAK-341 vs placebo on UMSARS Part I score change
Key Secondary Objectives Assess changes in UMSARS total score, CGI-S score, SCOPA-AUT, overall survival, CSF free αSYN levels
Study Duration 52 weeks
Administration Route Intravenous
Key Inclusion Criteria Age ≥40, MSA diagnosis, symptom onset ≤4 years, specific UMSARS scores
Key Assessments UMSARS, CGI-S, SCOPA-AUT, CSF analysis, safety monitoring

FAQ

  • What is Multiple System Atrophy (MSA)? Multiple System Atrophy (MSA) is a rare neurological disorder that affects multiple parts of the nervous system. It causes a combination of symptoms, including problems with movement, balance, and automatic body functions like blood pressure regulation.
  • What is TAK-341? TAK-341 is a Human IgG1 Lambda Monoclonal Antibody Against Alfa-Synuclein. It is an investigational drug being studied for its potential to treat Multiple System Atrophy. The drug is administered intravenously and targets the alfa-synuclein protein, which is believed to play a role in the development of MSA.
  • What are the main objectives of the clinical trial? The main objectives of the trial are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-341 in patients with Multiple System Atrophy. The study aims to measure changes in disease progression using various rating scales and assess the drug's effects on patients' symptoms and quality of life.
  • Who can participate in this clinical trial? Participants must be at least 40 years old, diagnosed with possible or probable MSA, have had symptoms for 4 years or less, and meet specific criteria related to disease severity. They must also have sufficiently intact cognition and be able to comply with study procedures. There are additional inclusion and exclusion criteria that the study team will assess.
  • How long does the clinical trial last? The clinical trial lasts for 52 weeks (1 year). During this time, participants will receive either TAK-341 or a placebo, and their progress will be monitored through various assessments and tests. The study also includes follow-up evaluations to assess long-term effects and safety.

Ongoing Clinical Trials on Human Igg1 Lambda Monoclonal Antibody Against Alfa-Synuclein

  • Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Italy Portugal +1

Glossary

  • Multiple System Atrophy (MSA): A rare, progressive neurological disorder that affects multiple parts of the nervous system, causing problems with movement, balance, and automatic body functions.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, it targets alfa-synuclein protein.
  • Alfa-Synuclein: A protein found in the brain that is believed to play a role in the development of certain neurological disorders, including Multiple System Atrophy.
  • Placebo: A substance that has no therapeutic effect, used as a control in testing new drugs.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • UMSARS: Unified Multiple System Atrophy Rating Scale, a tool used to assess the severity and progression of MSA symptoms.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, often used in tests to diagnose or monitor neurological conditions.
  • Intravenous (IV): Administered directly into a vein.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-tak-341-for-patients-with-multiple-system-atrophy/